Related Experiment Video
Updated: May 20, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
Published on: April 16, 2019
Can NASH be diagnosed, graded, and staged noninvasively?
Garfield A Grandison1, Paul Angulo
1Division of Digestive Diseases & Nutrition, Department of Medicine, University of Kentucky Medical Center, Lexington, 40536-0298, USA.
Clinics in Liver Disease
|July 25, 2012
Summary
Nonalcoholic fatty liver disease (NAFLD) includes nonalcoholic bland steatosis and nonalcoholic steatohepatitis (NASH). Liver biopsy is the gold standard for diagnosing NASH and staging fibrosis, though noninvasive methods show promise.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH).
- NASH can progress to advanced liver disease, including cirrhosis and hepatocellular carcinoma.
- Accurate diagnosis and staging of fibrosis are crucial for patient management.
Purpose of the Study:
- To review current diagnostic methods for NASH and fibrosis staging in NAFLD.
- To evaluate the role of liver biopsy versus noninvasive markers and imaging.
Main Methods:
- Review of existing literature on NAFLD diagnosis and fibrosis assessment.
- Discussion of liver biopsy as the gold standard.
- Exploration of noninvasive biomarkers (e.g., hepatocyte apoptosis markers) and imaging techniques.
Main Results:
- Liver biopsy remains the definitive method for distinguishing NASH from simple steatosis and staging liver fibrosis.
- Noninvasive biomarkers and scoring systems show potential for predicting fibrosis severity.
- Current noninvasive imaging modalities are valuable but do not yet replace liver biopsy for definitive assessment.
Conclusions:
- While liver biopsy is essential, ongoing research into noninvasive methods offers hope for simpler NASH diagnosis and fibrosis staging.
- Hepatocyte apoptosis markers and advanced imaging may improve noninvasive assessment of NAFLD progression.
- Further validation of noninvasive tools is needed to potentially obviate the need for liver biopsy in some patients.
Related Concept Videos
01:29Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...